Annual open meeting of the European Network of Paediatric Research at EMA (Enpr-EMA) November 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 November 2025, 09:00 (CET) to 20 November 2025, 16:45 (CET)

Submitted by Anonymous (not verified) on 18 August 2025 - 13:45

Annual open meeting of the European Network of Paediatric Research at EMA (Enpr-EMA) November 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 November 2025, 09:00 (CET) to 20 November 2025, 16:45 (CET)

Human medicines European public assessment report (EPAR): Fluenz Tetra, influenza vaccine (live attenuated, nasal), Date of authorisation: 04/12/2013, Revision: 24, Status: Withdrawn

Submitted by Anonymous (not verified) on 14 August 2025 - 17:10

Human medicines European public assessment report (EPAR): Fluenz Tetra, influenza vaccine (live attenuated, nasal), Date of authorisation: 04/12/2013, Revision: 24, Status: Withdrawn

Human medicines European public assessment report (EPAR): Sixmo, buprenorphine, Date of authorisation: 19/06/2019, Revision: 6, Status: Withdrawn

Submitted by Anonymous (not verified) on 14 August 2025 - 17:00

Human medicines European public assessment report (EPAR): Sixmo, buprenorphine, Date of authorisation: 19/06/2019, Revision: 6, Status: Withdrawn

Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Date of authorisation: 17/07/2015, Revision: 66, Status: Authorised

Submitted by Anonymous (not verified) on 14 August 2025 - 16:49

Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Date of authorisation: 17/07/2015, Revision: 66, Status: Authorised

EFIM Announces New Partnership with AMBOSS

Submitted by Aneta on 14 August 2025 - 16:00

We are delighted to announce a new partnership between EFIM and AMBOSS, a leading medical knowledge platform known for its high-quality content, innovative technology, and commitment to meeting physicians’ needs.

AMBOSS is offering exclusive Benefits for EFIM-Member Societies
All EFIM ordinary and associate member societies will receive special, ongoing benefits for their members:

Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 9, Status: Authorised

Submitted by Anonymous (not verified) on 14 August 2025 - 15:54

Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 9, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness